BUFFALO, NY--(Marketwire - December 12, 2007) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the results of a study of the effects of CBLB612, the lead compound in the Protectans 600 series, on propagation and mobilization to peripheral blood of hematopoietic (bone marrow/blood) stem cells (HSC) in comparison with G-CSF, the current market leading product, in mice.
